IDentif.AI Online

This resource is based on a recently completed study that harnessed the IDentif.AI platform to experimentally pinpoint a broad spectrum of potential combinations against SARS-CoV-2. IDentif.AI does not use in silico modelling or synergy predictions. Instead, it pairs prospective experimental validation with an optimisation process to provide a list of regimens, which can be explored through this interactive resource, for further consideration. This database will be updated as additional candidate therapies are assessed. Further information can be found here.

Drug Combination

(Maximum 4 drugs*)

IDentif.AI Derived

Invalid drug combination

SARS-CoV-2 Inhibition rank

0/9968

                
                        Vero E6 Inhibition
                        Vero E6 Cytotoxicity
                        AC16 Cytotoxicity
                        THLE-2 Cytotoxicity
                    
                        0%
                        0%
                        0%
                        0%

Vero E6 Inhibition	Vero E6 Cytotoxicity	AC16 Cytotoxicity	THLE-2 Cytotoxicity
0%	0%	0%	0%

  Vero E6: Kidney Epithelial Cells 

  AC16: Liver Epithelial Cells 

  THLE-2: Cardiomyocytes

IMPORTANT NOTE: This resource is being provided for research purposes only. These results are derived from the use of IDentif.AI against a patient-derived live coronavirus, and NOT a prospective, randomised human trial. Properly designed and regulated human trials with all applicable ethics board approvals must be conducted in order to clinically evaluate the combinations. Do not initiate treatment without the guidance of a medical professional with accredited expertise and training to recommend therapy for COVID-19.